Nirvana Life Sciences Inc.

The Canadian-based psychedelics company Nirvana Life Sciences Inc. filed a patent for the deuterated form of 7-hydroxymitragynine (D7-h.), commonly known as Kratom. Nirvana focuses on developing mental health therapeutics including non-addictive chronic pain and relapse-...

Nirvana Life Sciences Inc. (CSE: NIRV) announced that it has engineered a method that reduces the manufacturing time of MDMA by two thirds. The 3-step synthesis starts from the MDMA precursor safrole and takes only 24 hours to complete depending on which reduction method of...

Canada's Nirvana Life Sciences Inc. recently acquired a license for a novel delivery system for its psychedelics-based therapies currently in development. The company, which seeks to develop psychedelic therapeutic medicines including non-addictive chronic pain and relapse-...

Canadian life sciences company Nirvana Life Sciences Inc. (CSE: NIRV), focused on research & development of non-addictive pain management and relapse prevention products for pain and addictions, has been granted approval to build its R&D facility in Vancouver by Canada’s governmental...